Vigil Neuroscience Inc (NASDAQ:VIGL) has a beta value of 1.89 and has seen 3.45 million shares traded in the last trading session. The company, currently valued at $89.93M, closed the last trade at $2.20 per share which meant it lost -$0.15 on the day or -6.38% during that session. The VIGL stock price is -175.45% off its 52-week high price of $6.06 and 32.27% above the 52-week low of $1.49. If we look at the company’s 10-day average daily trading volume, we find that it stood at 4.75 million shares traded. The 3-month trading volume is 921.76K shares.
The consensus among analysts is that Vigil Neuroscience Inc (VIGL) is Buy stock at the moment, with a recommendation rating of 1.44. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 2 have rated it as a Hold, with 2 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.47.
Vigil Neuroscience Inc (NASDAQ:VIGL) trade information
Sporting -6.38% in the red in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the VIGL stock price touched $2.20 or saw a rise of 25.17%. Year-to-date, Vigil Neuroscience Inc shares have moved 29.41%, while the 5-day performance has seen it change 16.40%. Over the past 30 days, the shares of Vigil Neuroscience Inc (NASDAQ:VIGL) have changed 29.41%. Short interest in the company has seen 0.51 million shares shorted with days to cover at 5.31.
Wall Street analysts have a consensus price target for the stock at $11, which means that the shares’ value could jump 80.0% from current levels. The projected low price target is $11.0 while the price target rests at a high of $11.0. In that case, then, we find that the current price level is -400.0% off the targeted high while a plunge would see the stock gain -400.0% from current levels.
Vigil Neuroscience Inc (VIGL) estimates and forecasts
Figures show that Vigil Neuroscience Inc shares have underperformed across the wider relevant industry. The company’s shares have lost -48.24% over the past 6 months, with this year growth rate of 2.82%, compared to 16.40% for the industry. Revenue growth from the last financial year stood is estimated to be 0.00%.
Earnings growth for 2025 is a modest 4.38% while over the next 5 years, the company’s earnings are expected to increase by 8.09%.
VIGL Dividends
Vigil Neuroscience Inc is expected to release its next earnings report in February this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Vigil Neuroscience Inc (NASDAQ:VIGL)’s Major holders
Insiders own 21.27% of the company shares, while shares held by institutions stand at 80.16% with a share float percentage of 101.81%. Investors are also buoyed by the number of investors in a company, with Vigil Neuroscience Inc having a total of 77.0 institutions that hold shares in the company. The top two institutional holders are ATLAS VENTURE LIFE SCIENCE ADVISORS, LLC with over 5.84 million shares worth more than $23.35 million. As of 2024-06-30, ATLAS VENTURE LIFE SCIENCE ADVISORS, LLC held 14.6419% of shares outstanding.
The other major institutional holder is NORTHPOND VENTURES, LLC, with the holding of over 4.21 million shares as of 2024-06-30. The firm’s total holdings are worth over $16.86 million and represent 10.5722% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and abrdn Life Sciences Investors . As of Sep 30, 2024 , the former fund manager holds about 1.74% shares in the company for having 710.14 shares of worth $1.56 million while later fund manager owns 235.01 shares of worth $0.52 million as of Sep 30, 2024 , which makes it owner of about 0.57% of company’s outstanding stock.
